Plasma steroid and protein hormone concentrations in patients with benign prostatic hypertrophy and in normal men

Ortega, Esperanza; Ruiz, Enrique Martínez; Mendoza, Magdalena; Martín-Andrés, Antonio

doi:10.1007/bf01968288

Cited by 11 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is supported by previous evidence of reduced plasma T levels and elevated plasma estradiol (E2) levels in patients with BPH [30], [31] and of a higher E2/T ratio in aging men at greater risk of prostate disease [28]. However, the variation in serum concentrations of E2 may not accurately reflect intraprostatic levels, because E2 is produced from T by the enzyme aromatase (CYP19A1, EC1.14.14.1), which interestingly is increased in the malignant human prostate [32].…”

Section: Introductionsupporting

confidence: 68%

Bisphenol A Exposure during Adulthood Alters Expression of Aromatase and 5α-Reductase Isozymes in Rat Prostate

et al. 2013

View full text Add to dashboard Cite

The high incidence of prostate cancer (PCa) and benign prostatic hypertrophy (BPH) in elderly men is a cause of increasing public health concern. In recent years, various environmental endocrine disruptors, such as bisphenol A (BPA), have been shown to disrupt sexual organs, including the prostate gland. However, the mechanisms underlying these effects remain unclear. Because androgens and estrogens are important factors in prostate physiopathology, our objective was to examine in rat ventral prostate the effects of adult exposure to BPA on 5α-Reductase isozymes (5α-R types 1, 2, and 3) and aromatase, key enzymes in the biosynthesis of dihydrotestosterone and estradiol, respectively. Adult rats were subcutaneously injected for four days with BPA (25, 50, 300, or 600 µg/Kg/d) dissolved in vehicle. Quantitative RT-PCR, western blot and immunohistochemical analyses showed lower mRNA and protein levels of 5α-R1 and 5α-R2 in BPA-treated groups versus controls but higher mRNA levels of 5α-R3, recently proposed as a biomarker of malignancy. However, BPA treatment augmented mRNA and protein levels of aromatase, whose increase has been described in prostate diseases. BPA-treated rats also evidenced a higher plasma estradiol/testosterone ratio, which is associated with prostate disease. Our results may offer new insights into the role of BPA in the development of prostate disease and may be of great value for studying the prostate disease risk associated with exposure to BPA in adulthood.

show abstract

Section: Introductionsupporting

confidence: 68%

Bisphenol A Exposure during Adulthood Alters Expression of Aromatase and 5α-Reductase Isozymes in Rat Prostate

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Regarding the plasma levels of other hormones, while testosterone levels show a significant decrease in BPH patients, no significant alteration could be shown with respect to FSH, LH, prolactin and estradiol levels [10]. While it has been reported that serum LH, FSH and progesterone levels have been found to be more elevated in patients with BPH than the control cases [11], in their original study Sasagawa et al [7] have been able to show that plasma prolactin levels are elevated more significant- 5.…”

Section: Discussionmentioning

confidence: 99%

Effects of Transurethral Prostate Resection and Transurethral Laser Prostatectomy on Plasma Hormone Levels

Türkölmez

Bozlu

Sarıca³

et al. 1998

Urol Int

View full text Add to dashboard Cite

Objective: The short and long-term effects of two common transurethral procedures (TURP and TULP, transurethral prostatic resection and laser prostatectomy, respectively) on plasma hormone levels in patients with benign prostatic hyperplasia (BPH) have been evaluated. Patients and Methods: Totally 57 patients with histologically proven BPH (age range 54–81 years, mean 62.5 years) were included into the study program. Of these 57 patients, 44 underwent TURP and 13 underwent TULP for treatment of their bladder outlet obstructions. 20 patients with bladder cancer undergoing transurethral resection (n = 15) and those undergoing transurethral laser ablation (n = 5) constituted the control group. Plasma luteinizing hormone (LH), prolactin (PRL), follicle-stimulating hormone (FSH), adrenocorticotrophic hormone (ACTH), cortisol, aldosterone, dihydroepiandrosterone sulfate (DHEA-S) and testosterone levels were assessed in all patients before and after 3 weeks and 3 months following the aforementioned procedures. Comparative evaluation of the results with respect to the effect of different procedures have been made between study and control groups. Results: Preoperatively, we were not able to demonstrate any significant difference with respect to all but plasma prolactin levels (p < 0.05) between the study and control groups. Prolactin levels were found to be significantly higher in BPH patients. In BPH patients undergoing TURP, while LH levels were significantly higher during the 3 weeks’ evaluation (p < 0.001) no significant difference could be shown during the 3 months’ examination (p > 0.05). Again, prolactin levels did significantly decline (p < 0.05) in patients undergoing TURP during the 3 weeks’ follow-up evaluation, no difference was present 3 months postprocedure. On the other hand, in patients undergoing TULP, while we were not able to show any significant difference with respect to plasma prolactin levels (p > 0.05) pre- and postoperatively, plasma LH levels were significantly increased during the 3-month evaluation (p < 0.05). Conclusions: Alterations in the plasma levels of LH and prolactin following prostatectomy during follow-up evaluation, led the physicians to consider possible effects of some factors released from resected prostate gland. Behavior of prolactin and LH after TURP and laser ablation is quite different in our study. It may be related to the higher amount of residual prostate tissue after TULP. On the other hand, normalization of hormone levels 3 months following TURP, led us to think about the activation of some factors responsible for hormonal regulation which in turn institutes a new hormonal balance.

show abstract

“…On the other hand, the changes of plasma estrogen concentration in BPH patients remain controversial. Drafta et a1 [ 121 found a decrease of plasma estrone and estradiol levels in BPH patients, whereas several authors [2,13,14] have demonstrated no significant effect on estrogen. The present study was undertaken to demonstrate any difference in circulating unconjugated and glucuronide derivatives of progestins, androgens, and estrogens between patients with BPH and age matched controls.…”

Section: Introductionmentioning

confidence: 99%

Comparative Study of Plasma Steroid and Steroid Glucuronide Levels in Normal Men and in Men With Benign Prostatic Hyperplasia

Brochu

Bélanger

1988

Journal of Urology

View full text Add to dashboard Cite

Plasma steroids were analyzed in 16 normal men and in 10 men with prostatic benign hyperplasia (BPH). The steroids measured by radioimmunoassay include pregnenolone, 17-OH-pregnenolone, dehydroepiandrosterone, androst-5-ene-36, 170-dio1, testosterone, dihydrotestosterone, androstane-3q 17P-dio1, androstane-36, 17P-dio1, estrone, and estradiol as well as their glucuronide derivatives. In addition, cortisol and the sulphoconjugated form of dehydroepiandrosterone were determined. Whereas the levels of pregnenolone, pregnenolone glucuronide and 17-OH-pregnenolone glucuronide are not different in the two groups, the levels of 17-OH-pregnenolone in the BPH group (0.87 f 0.07 ng/ml) exceed by twofold (p < 0.01) those observed in normal men. Plasma dehydroepiandrosterone and androst-5-ene-36, 176-diol concentrations are markedly elevated in the BPH group (1.49 + 0.23 and 0.55 f 0.08 ngiml vs the control groups 0.43 & 0.11 and 0.31 + 0.05 ng/ml, respectively). Since the plasma cortisol and pregnenolone levels are comparable in these two groups, our data suggest that the elevation of plasma 17-OH-pregnenolone, dehydroepiandrosterone, and androst-5-ene-36, 176-diol reflects an increase of adrenal 17-hydroxylase activity in patients with BPH. A slight increase of the plasma dihydrotestosterone and androsterone glucuronide concentration is also observed in men with BPH, indicating an increase of 5a-reduced androgen formation. We have also observed, in the BPH group, a 50% decrease (p < 0.01) of plasma glucuronidated androst-5-ene-30,170-diol, estrone, and estradiol levels, suggesting that the transformation of unconjugated estrogenic steroids into glucuronide derivative is inhibited in BPH patients. In summary, our data indicate that adrenal C-19 steroids might be involved in the process of BPH. Furthermore, whereas the estrogen glucuronide formation is diminished in men with BPH, the prostatic androgen metabolism as reflected by plasma dihydrotestosterone and androsterone glucuronide concentrations seems to be increased.

show abstract

Plasma steroid and protein hormone concentrations in patients with benign prostatic hypertrophy and in normal men

Cited by 11 publications

References 14 publications

Bisphenol A Exposure during Adulthood Alters Expression of Aromatase and 5α-Reductase Isozymes in Rat Prostate

Bisphenol A Exposure during Adulthood Alters Expression of Aromatase and 5α-Reductase Isozymes in Rat Prostate

Effects of Transurethral Prostate Resection and Transurethral Laser Prostatectomy on Plasma Hormone Levels

Comparative Study of Plasma Steroid and Steroid Glucuronide Levels in Normal Men and in Men With Benign Prostatic Hyperplasia

Contact Info

Product

Resources

About